Plasma levels of transforming growth factor-1β and α2-macrogfobulin before and after radical prostatectomy: Association to clinicopathological parameters

Prostate

Volumn 61, Issue 3, 2004, Pages 201-208

  Sinnreich, O ^a   Kratzsch, J ^b   Reichenbach, A ^b   Glaser C ^c   Huse, K ^d   Birkenmeier, G ^b  

^a Klinikum St Georg   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^d FRITZ LIPMANN INSTITUTE   (Germany)

Author keywords

2 macroglobulin; Body mass index; Prostate; Prostate cancer; Prostate specific antigen; Prostatectomy; Transforming growth factor 1

Indexed keywords

ALPHA 2 MACROGLOBULIN; BINDING PROTEIN; PROSTATE SPECIFIC ANTIGEN; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ANDROGEN THERAPY; ARTICLE; BLOOD LEVEL; BODY MASS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROSTATECTOMY; RISK FACTOR;

AGED; ALPHA-MACROGLOBULINS; BODY MASS INDEX; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKERS, BIOLOGICAL;

EID: 5344223482     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20062     Document Type: Article

References (27)

1. Weir HK, Thun MJ, Hankey BF, Ries LAG, Howe HL, Wingo PA, Jemal A, Ward E, Anderson RN, Edwards L. Annual report to the nation on the status of cancer 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 2003;95:1276-1299.
2. Wikstrom P, Bergh A, Damber JE. Transforming growth factor-beta1 and prostate cancer. Scand J Urol Nephrol 2000;34:85-94.
3. Christensson A, Laurell CB, Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 1990;194:755-763.
4. Otto A, Bär J, Birkenmeier G. Prostate-specific antigen forms complexes with human alpha 2-macroglobulin and binds to the alpha 2-macroglobulin receptor/LDL receptor-related protein. J Urol 1998;159:297-303.
5. Crookston KP, Webb DJ, Lamarre J, Gonias SL. Binding of platelet-derived growth factor-BB and transforming growth factor-beta 1 to alpha 2-macroglobulin in vitro and in vivo: Comparison of receptor-recognized and non-recognized alpha 2-macroglobulin conformations. Biochem J 1993;293:443-450.
6. Tuxhorn JA, McAlhany SJ, Yang F, Dang TD, Rowley DR. Inhibition of transforming growth factor-beta activity decreases angiogenesis in a human prostate cancer-reactive stroma xenograft model. Cancer Res 2002;62:6021-6025.
7. Pasche B. Role of transforming growth factor beta in cancer. J Cell Physiol 2001;186:153-168.
8. Shariat SF, Shalev M, Menesses-Diaz A, Kim IY, Kattan MW, Wheeler TM. Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. J Clin Oncol 2001;19:2856-2864.
9. Kattan MW, Shariat SF, Andrews B, Zhu K, Canto E, Matsumoto K, Muramoto M, Scardino PL, Ohori M, Wheezer TM, Seawin KM. The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. J Clin Oncol 2003 (in press).
10. Xie B, Tsao SW, Wong Y. Sex hormone-induced mammary carcinogenesis in female Noble rats: Expression of TGF-beta1 and its receptors, TGF-alpha, and EGF-R in mammary carcinogenesis. Breast Cancer Res Treat 1999;58:227-239.
11. Zatelli MC, Rossi R, degli Uberti EC. Androgen influences transforming growth factor-beta1 gene expression in human adrenocortical cells. J Clin Endocrinol Metab 2000;85:847-852.
12. Kim IY, Kim JH, Zelner DJ, Ahn HJ, Sensibar JA, Lee C. Transforming growth factor-beta1 is a mediator of androgen-regulated growth arrest in an androgen-responsive prostatic cancer cell line, LNCaP. Endocrinology 1996;137:991-999.
13. Porreca E, Di Febbo C, Vitacolonna E, Baccante G, Di Castelnuovo A, Angelici A, Febo F, Di Nisio M, Cuccurullo F. Transforming growth factor-beta1 levels in hypertensive patients: Association with body mass index and leptin. Am J Hypertens 2002;15:759-765.
14. Saxe GA, Hebert JR, Carmody JF, Kabat-Zinn J, Rosenzweig PH, Jarzobski D, et al. Can diet in conjunction with stress reduction affect the rate of increase in prostate specific antigen after biochemical recurrence of prostate cancer? J Urol 2001;166:2202-2207.
15. Clinton SK, Palmer SS, Spriggs CE, Visek WJ. Growth of Dunning transplantable prostate adenocarcinomas in rats fed diets with various fat contents. J Nutr 1988;118:908-914.
16. Webb DJ, Wen J, Karns LR, Kurilla MG, Gonias SL. Localization of the binding site for transforming growth factor-beta in human alpha2-macroglobulin to a 20-kDa peptide that also contains the bait region. J Biol Chem 1998;273:13339-13346.
17. Harthun NL, Weaver AM, Brinckerhoff LH, Deacon DH, Gonias SL, Slingluff CL Jr. Activated alpha 2-macroglobulin reverses the immunosuppressive activity in human breast cancer cell-conditioned medium by selectively neutralizing transforming growth factor-beta in the presence of interleukin-2. J Immunother 1998;21:85-94.
18. Birkenmeier G, Muller R, Huse K, Forberg J, Glaser C, Hedrich H, et al. Human alpha2-macroglobulin: Genotype-phenotype relation. Exp Neurol 2003 (in press).
19. Kanoh Y, Ohtani N, Mashiko T, Ohtani S, Nishikawa T, Egawa S, et al. Levels of alpha 2 macroglobulin can predict bone metastases in prostate cancer. Anticancer Res 2001;21:551-556.
20. Cohen P, Peehl DM, Graves HC, Rosenfeld RG. Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease. J Endocrinol 1994;142:407-415.
21. Kennedy-Smith AG, McKenzie JL, Owen MC, Davidson PJ, Vuckovic S, Hart DN. Prostate specific antigen inhibits immune responses in vitro: A potential role in prostate cancer. J Urol 2002;168:741-774.
22. Gygi CM, Leibovitch IY, Adlington R, Baldwin JE, Chen B, Mccoull W, et al. Prostate-specific antigen (PSA)-mediated proliferation, androgenic regulation and inhibitory effects of LY312340 in HOS-TE85 (TE85) human osteosarcoma cells. Anticancer Res 2002;22:2725-2732.
23. Heidtmann HH, Nettelbeck DM, Mingels A, Jager R, Welker HG, Kontermann RE. Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen. Br J Cancer 1999;81:1269-1273.
24. Paczek L, Gaciong Z, Bartlomiejczyk I, Sebekova K, Birkenmeier G, Heidland A. Protease administration decreases enhanced transforming growth factor-beta 1 content in isolated glomeruli of diabetic rats. Drugs Exp Clin Res 2001;27:141-149.
25. Desser L, Holomanova D, Zavadova E, Pavelka K, Mohr T, Herbacek I. Oral therapy with proteolytic enzymes decreases excessive TGF-beta levels in human blood. Cancer Chemother Pharmacol 2001;47:10-15.
26. Djavan B, Waldert M, Seitz C, Marberger M. Insulin-like growth factors and prostate cancer. World J Urol 2001;19:225-233.
27. Stattin P, Soderberg S, Hallmans G, Bylund A, Kaaks R, Stenman UH, et al. Leptin is associated with increased prostate cancer risk: A nested case-referent study. J Clin Endocrinol Metab 2001;86:1341-1345.